	US 12,268,677 B2
	4-aminopyridine (4-AP) and bone morphogenetic protein 2 (BMP-2)
Sandeep Moothedath Subrahmanian, University Park, PA (US); Prem Kumar Govindappa, University Park, PA (US); and John Elfar, Hummelstown, PA (US)
Assigned to The Penn State Research Foundation, University Park, PA (US)
Filed by The Penn State Research Foundation, University Park, PA (US)
Filed on Apr. 27, 2023, as Appl. No. 18/140,258.
Claims priority of provisional application 63/335,349, filed on Apr. 27, 2022.
Prior Publication US 2023/0346758 A1, Nov. 2, 2023
Int. Cl. A61K 31/4409 (2006.01); A61P 19/08 (2006.01)

CPC A61K 31/4409 (2013.01) [A61P 19/08 (2018.01)]

9 Claims

1. A method for treating a mammal having osteoporosis, a bone cancer, a congenital bone disease, a degenerative bone disease, a dietary bone insufficiency, or an environmental exposure bone insufficiency, wherein said method comprises:

(a) administering a composition comprising 4-aminopyridine (4-AP), 3,4-diaminopyridine, 3-hydroxy-4-aminopyridine, N-(4-pyridyl)-t-butyl carbamate, N-(4-pyridyl) ethyl carbamate, N-(4-pyridyl) methyl carbamate, N-(4-pyridyl) isopropyl carbamate, or a pharmaceutically acceptable salt thereof to said mammal, wherein said administering comprises a systemic administration; and

(b) detecting an increased level of a BMP-2 polypeptide in a sample obtained from said mammal.